表紙:糖尿病性足潰瘍 : パイプライン製品の分析
市場調査レポート
商品コード
192554

糖尿病性足潰瘍 : パイプライン製品の分析

Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 218 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.57円
糖尿病性足潰瘍 : パイプライン製品の分析
出版日: 2021年10月31日
発行: Global Markets Direct
ページ情報: 英文 218 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病性足潰瘍とは、1型・2型糖尿病の患者の足部に生じる爛れた部分のことです。主な症状には、足部・下脚の爛れ・潰瘍・水疱や、歩行困難、足の変色(黒・青・赤)、足部の体温低下または発熱、皮膚が赤く腫れあがること、その他の感染症の徴候などが挙げられます。疾病素質には、糖尿病性神経障害や末梢血管疾患、足部変形、喫煙関連の病歴などがあります。

当レポートでは、世界各国での糖尿病性足潰瘍治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性足潰瘍の概要

治療薬の開発

  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • ANP Technologies Inc
  • Anterogen Co Ltd
  • Boston Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Chrysalis BioTherapeutics Inc
  • CytoTools AG
  • EyeGene Inc
  • FirstString Research Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Human Stem Cells Institute
  • Izun Pharmaceuticals Corp
  • Lakewood-Amedex Inc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Oneness Biotech Co Ltd
  • Osiris Therapeutics Inc
  • Pherecydes Pharma SA
  • RMB-Research GmbH
  • Serodus ASA
  • Stempeutics Research Pvt Ltd
  • Stratatech Corp
  • TechnoPhage SA
  • Theravasc Inc
  • Topadur Pharma AG
  • USV Pvt Ltd
  • viDA Therapeutics Inc
  • ViroMed Co Ltd

薬剤のプロファイル

糖尿病性足潰瘍治療薬:開発が休止状態の製品

糖尿病性足潰瘍治療薬:開発が中止された製品

糖尿病性足潰瘍関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for Diabetic Foot Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Diabetic Foot Ulcers - Pipeline by Alan Laboratories Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Aposcience AG, 2021
  • Diabetic Foot Ulcers - Pipeline by Aprogen Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by APstem Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by AptaBio Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Aurealis Therapeutics AG, 2021
  • Diabetic Foot Ulcers - Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Biofilm Pharma, 2021
  • Diabetic Foot Ulcers - Pipeline by Blue Blood Biotech Corp, 2021
  • Diabetic Foot Ulcers - Pipeline by Canton Biotechnologies Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Cellics Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Cellresearch Corp Pte Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Celularity Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Chiesi Farmaceutici SpA, 2021
  • Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Crescita Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by CSA Biotechnologies LLC, 2021
  • Diabetic Foot Ulcers - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021
  • Diabetic Foot Ulcers - Dormant Projects, 2021
  • Diabetic Foot Ulcers - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Diabetic Foot Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
目次
Product Code: GMDHC13114IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 20, 10, 2, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Diabetic Foot Ulcers - Overview
  • Diabetic Foot Ulcers - Therapeutics Development
  • Diabetic Foot Ulcers - Therapeutics Assessment
  • Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
  • Diabetic Foot Ulcers - Drug Profiles
  • Diabetic Foot Ulcers - Dormant Projects
  • Diabetic Foot Ulcers - Discontinued Products
  • Diabetic Foot Ulcers - Product Development Milestones
  • Appendix